Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00132379 · ClinicalTrials.gov registry record · Phase 1

ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer

A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Active Biotech AB.

Completed
Registry status
Phase 1
Development phase
13
Enrollment target
4
Study locations

NCT00132379 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that has completed, run by Active Biotech AB. The registered enrollment target is 13 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00132379, a Phase 1 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Active Biotech AB.

COMPLETED
Registry status
Phase 1
Development phase
13 participants
Enrollment target
4
Study locations

Study Summary

The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system. In animals, this results in an accumulation of white blood cells in the cancer that can fight the cancer. This study will test how much of the drug, in combination with docetaxel (an approved drug for treating non-small cell lung cancer \[NSCLC\]), can be given to patients with NSCLC without causing unacceptable side effects.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG docetaxel
  • DRUG ABR-217620

Study Locations (4)

Other

  • Onkologisk Klinik, Rigshospitalet - Copenhagen
  • City Multifield Hospital #2, City Center of Intensive Pulmonology and Thoracic Surgery - Saint Petersburg
  • St. Petersburg Pavlov State Medical University - Saint Petersburg

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2005-11
Est. Completion 2006-12
Phase Phase 1

Sponsor

Active Biotech AB

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00132379

The ClinicalTrials.gov registry entry for NCT00132379 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (96% lower). The listed sponsor is Active Biotech AB, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.

NCT00132379 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00132379 about?

NCT00132379 is a clinical study titled "ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer". The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system. In animals, this results in an accumulation of white blood cells in the cancer t...

What is the current status of trial NCT00132379?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2005-11. Estimated completion is 2006-12.

What conditions does trial NCT00132379 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT00132379?

The interventions under investigation include: docetaxel (DRUG), ABR-217620 (DRUG).

Who is sponsoring clinical trial NCT00132379?

This trial is sponsored by Active Biotech AB, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00132379 being conducted?

This trial has 4 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.